Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy: A nested case control study

Huy A Tran\textsuperscript{1*}, Tracey L Jones\textsuperscript{2†}, Robert Gibson\textsuperscript{2†} and Glenn EM Reeves\textsuperscript{1†}

Abstract

Background: Interferon-\textalpha\textsubscript{a} in combination with ribavirin is the current gold standard for treatment of chronic hepatitis C. It is unknown if the development of autoimmune thyroid disease (TD) during treatment confers an improved chance of achieving sustained virologic response. The aim of this study is to assess the chance of achieving sustained virologic response (SVR) in patients who developed TD during treatment when compared with those who did not.

Methods: We performed a tertiary hospital-based retrospective nested case-control analysis of 19 patients treated for hepatitis C who developed thyroid disease, and 76 controls (matched for age, weight, gender, cirrhosis and aminotransferase levels) who did not develop TD during treatment. Multivariate logistic-regression models were used to compare cases and controls.

Results: The development of TD was associated with a high likelihood of achieving SVR (odds ratio, 6.0; 95\% confidence interval, 1.5 to 24.6) for the pooled group containing all genotypes. The likelihood of achieving SVR was increased in individuals with genotype 1 HCV infection who developed TD (odds ratio, 5.2; 95\% confidence interval, 1.2 to 22.3), and all genotype 3 patients who developed TD achieved SVR.

Conclusions: Development of TD during treatment for hepatitis C infection is associated with a significantly increased chance of achieving SVR. The pathophysiologic mechanisms for this observation remain to be determined.

Trial Registration: The Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12610000830099

Background

Hepatitis C is one of the major global causes of chronic hepatic infections, particularly in third world countries, and is associated with a significant rate of cirrhosis and hepatoma. In Australia \cite{1,2} and the United States of America \cite{3,4}, the burden of disease is significant. Although the incidence has come under control, the associated sequelae unfortunately have been predicted to increase in the coming decades \cite{5}. Consequently, a large and growing number of patients will be expected to undergo treatment for hepatitis C. Of those receiving combination treatment with interferon (IFN)-\textalpha\textsubscript{a} and ribavirin (RBV), approximately 5-10\% will develop thyroid-related complications \cite{6}. Whilst there are a number of factors in the prediction of favourable hepatic outcome such as genotype, ethnicity, and early viral load reduction \cite{7,8}, there are few published reports that assess the development of thyroid disease (TD) in relation to sustained virological response (SVR). Our previous meta-analysis did not find any difference, although this may be due to inherent differences in the published reports \cite{9}. The aim of this study is to investigate the hypothesis that the development of TD in patients

* Correspondence: huy.tran@hnehealth.nsw.gov.au
† Contributed equally
1 Hunter Area Pathology Service and University of Newcastle, Locked Bag Number 1, Hunter Mail Region Centre, Newcastle, New South Wales 2310, Australia
Full list of author information is available at the end of the article

© 2011 Tran et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
treated for HCV is associated with a significantly increased likelihood of attaining SVR.

**Methods**

**Patients and control participants**

We enrolled 19 patients who developed TD while receiving combination therapy in a major tertiary referral hospital, New South Wales (NSW), Australia. These patients had been assessed by the endocrinology team. All were found to have thyroiditis as previously described [10], except one who developed primary hypothyroidism.

Patients were treated with predetermined IFN-based treatment regimen and thyroid surveillance protocol. Alternative causes of chronic hepatitis were excluded. No patient had dual Hepatitis B and C. All were monitored carefully for protocol adherence and had normal thyroid functions prior to entering treatment. Monthly reviews were performed, including those who developed TD (as defined below) with thyrotropin (TSH) levels, full blood counts, renal and liver function tests as previously described [10]. Thyroid autoantibodies, whilst predictive, were not performed as it did not affect management in the event of TD development.

Because of the scarcity of reported thyroid diseases in relation to SVR in the literature, we performed a nested case control study using a 1:4 ratio of cases to controls. Patients were matched for age, gender, viral load, body weight, alanine and aspartate aminotransferase levels, cirrhotic state and individualised IFN-α2 treatments (either α2a or α2b). The cirrhotic status was determined clinically including ultrasonography and/or computed tomography.

**Therapy**

All patients were treated with combination pegylated IFN-α and RBV therapy. Pegylated IFN-α2a (fixed dose 180 ug) or pegylated IFN-α2b (weight based dose, 1.5 ug/kg of body weight) was injected subcutaneously weekly. Oral RBV was administered twice daily base on the patient’s weight (1.0 gm, <75 kg; 1.2 gm, >75 kg) for patients with genotype 1 and the fixed dose (0.8 gm) for patients with non-1 genotype. The duration of treatment depends on the HCV genotypes; genotypes 2 and 3 were treated for 24 weeks and types 1 and 4 for 48 weeks respectively. Treatment was further adjudicated according to viral load results for genotypes 1 and 4 (see below).

For genotypes 2 & 3, treatment was continued to the end irrespective of the qualitative viral load at 4 weeks.

**Thyroid disease definition**

Thyroid disease was defined as having hypo- or hyperthyroidism, (clinically and biochemically based).

Thyrotoxicosis was defined as having TSH of <0.1 mU/L, fT4 levels >26.0 and/or fT3 levels >6.0 pmol/L respectively.

Hypothyroidism, including subclinical hypothyroidism, was defined as having TSH levels >4.0 mIU/L.

Thyroiditis is defined as the triad of clinical and/or biochemical thyrotoxicosis the current clinical setting, with a reduced/negligible thyroid pertechnetate uptake scan. All uptake scans were reviewed by a specialist nuclear physician consultant. Thyroid autoantibodies may be present but are not considered essential to the diagnosis.

**Virological Response Surveillance Protocol**

The following viral load testing protocols were used during the study:

1. Baseline quantitative HCV RNA PCR assays were performed on all patients irrespective of genotype.
2. For genotypes 1 and 4, qualitative viral load assays were done at weeks 4, 24, 48 and 24 weeks after the completion of therapy. Additional quantitative assay was done at week 12. Treatment was terminated if there was ≤ 2 log₁₀ reduction of viral load compared with baseline at the 12th week of therapy or if the qualitative viral load was positive at the 24th week.
3. For genotypes 2 & 3, qualitative viral load assay was done at week 4, 24 (at the completion of therapy) and at week 24 follow-up.

SVR was defined as serum HCV-RNA being undetectable by polymerase chain reaction (PCR) at 24 weeks following the completion of therapy.

**Statistical Analyses**

The study was designed to detect an odds ratio of 2 or more for associations between SVR and thyroid disease development, with 80% power. A 1:4 ratio of cases to controls was used, with significance tests performed at a two-tailed alpha level of 0.05. Odds ratios were adjusted for age, weight, gender and aminotransferase levels.

Unconditional multivariate logistic-regression analysis was used to estimated odds ratios and 95% confidence intervals (CIs). Statistical significance was determined using the likelihood-ratio test. Demographic data are presented as percentage and means with standard deviations (SDs). Results were also analysed using a 2 x 2 contingency table with χ² analysis for comparison of percentages between groups. The Fisher’s exact analysis and continuity correction were applied when appropriate. All analyses were performed using Stata 10 software (Stata).
Results
All subject cases had thyroiditis as previously defined except for one case of primary hypothyroidism and all patients were well matched for all stated criteria, Table 1.

Sustained virologic response was observed in 84.2% of patients who developed TD compared with 53.9% in those who did not. The difference between proportions was significant at 0.30 (95% Confidence Interval (CI), 0.10 - 0.50, p < 0.05).

Overall, univariate logistic regression analysis revealed that cases which developed TD, had a 6.0 times greater likelihood of achieving SVR compared with controls (95% confidence interval (CI), 1.5 to 24.6). The likelihood of achieving SVR was even greater for genotype 1 cases with TD versus those without TD (OR, 5.2; 95% CI, 1.2 to 22.3), and all genotype 3 patients who developed TD also achieved SVR, Table 2.

Multivariate logistic regression analysis showed that presence of TD and genotype was the only two variables significantly associated with SVR. Modelling with these two independent variables revealed that individuals who developed TD had a 6 folds greater likelihood of achieving SVR compared with controls (95% confidence interval (CI), 1.5 to 24.6).

Discussion
The prevalence of hepatitis C is now controlled in the Western world [5] but continues to increase in third world and developing countries due to lack of needle exchange program and medical infrastructure. In Australia, the numbers have stabilized and more recently declined [2]. The current established and accepted treatment for chronic hepatitis C infection is the combination of pegylated IFN-α and RBV. This treatment regimen delivers a cure rate of approximately 50% of cases [11]. The favourable factors in response to treatment include genotypes (2 and 3 genotypes have better response), compliance, duration of treatment and early

Table 1 Characteristics of 95 patients and separate case/control subjects

| Term                          | All Patients | Cases TD | Controls No TD | P-values | 95% CI |
|-------------------------------|--------------|----------|----------------|----------|--------|
| N = 95                        | N = 19       | N = 76   |                |          |        |
| Demographic factors           |              |          |                |          |        |
| Female gender - number (%)    | 55 (57.9%)   | 11 (57.9%) | 44 (57.9%)     | NSS      |        |
| Mean age (years) ± SD         | 47 ± 8       | 47 ± 8   | 48 ± 7         | NSS      |        |
| Weight (kg) ± SD              | 69.7 ± 10.1  | 70.6 ± 8.5 | 69.8 ± 10.7   | NSS      |        |
| Hepatic factors               |              |          |                |          |        |
| Cirrhosis - number (%)        | 5 (5.3%)     | 1 (5.3%) | 4 (5.3%)       | NSS      |        |
| ALT (<45 U/L) ± SD            | 54 ± 24      | 56 ± 26  | 53 ± 25        | NSS      |        |
| AST (1-30 U/L) ± SD           | 39 ± 11      | 41 ± 12  | 38 ± 12        | NSS      |        |
| Virologic factors             |              |          |                |          |        |
| Genotypes - number (%)        |              |          |                |          |        |
| • 1                           | 55 (58.0%)   | 11 (58.0%) | 44 (58.0%)     | NSS      |        |
| • 3                           | 40 (42.0%)   | 8 (42.0%) | 32 (42.0%)     | NSS      |        |
| Viral Load                    |              |          |                |          |        |
| - At baseline (log IU/mL) ± SD| 6.44 ± 0.52  | 6.22 ± 0.56 | 6.64 ± 0.53   | NSS      |        |
| Treatment regimens - number (%)|            |          |                |          |        |
| IFN-α2a together with         |              |          |                |          |        |
| Ribavirin                     |              |          |                |          |        |
| 1.0 gm (patients ≤ 75 kg)     | 20 (36.4%)   | 4 (36.4%) | 16 (36.4%)     |          |        |
| 1.2 gm (patients >75 kg)      | 15 (27.3%)   | 3 (27.3%) | 12 (27.3%)     |          |        |
| 0.8 gm                        | 20 (36.4%)   | 4 (36.4%) | 16 (36.4%)     |          |        |
| IFN-α2b together with         |              |          |                |          |        |
| Ribavirin                     |              |          |                |          |        |
| 1.0 gm (patients ≤ 75 kg)     | 10 (25.0%)   | 2 (25.0%) | 8 (25.0%)      |          |        |
| 1.2 gm (patients >75 kg)      | 10 (25.0%)   | 2 (25.0%) | 8 (25.0%)      |          |        |
| 0.8 gm                        | 20 (50.0%)   | 4 (50.0%) | 16 (50.0%)     |          |        |

Results are expressed as Means ± Standard Deviations (SDs). CI, Confidence Intervals; IFN, Interferon; NSS, Non Statistically Significant; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase.
viral load reduction [8]. Additional positive prognosticators consist of lower body mass index, lack of co-existing liver disease and ethnicity (Asians and Caucasians have a higher SVR than African Americans) [7]. The relationship between TD and SVR had been scarcely addressed and in our solitary meta-analysis, the outcome was negative [9].

Hypothetically, when treatment is delivered, the immune system is stimulated sufficiently in an attempt to eradicate the virus and in the process may also be intense enough to trigger TD, as an unintended consequence. Because the presence of TD may signify a supercharged and heightened immune response which in turn increases the chance of eradicating the virus. Studies have shown that in patients who developed TD, immune marker levels such as Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-α) and chemokines are relatively higher and thus in the process may potentially be more effective at achieving SVR [12]. Furthermore, the presence of thyroid hormones in vitro also potentiates the antiviral action of IFN in cultured human cells [13]. This hypothesis was observed in our previous report in which all 11 IFN-related thyroid cases achieved SVR [10]. However, a subsequent meta-analysis failed to find any relationship although this might be due to inherent differences within the various reports [9]. This additional nested case control study in which the cases were matched in a ratio of 1 case to 4 controls finds further supportive evidence that the development of TD in HCV patients whilst undergoing combination with RBV and IFN-α treatment is a favorable prognostic factor for achieving SVR. It is reassuring that other factors are matched including age, gender, weight, viral load, cirrhosis and transaminase levels; some of which can influence final SVR status. It is also interesting that there was one primary hypothyroid case which was clearly not the hypothyroid phase of the thyroiditis. In this case, the patient responded well to routine thyroxine supplement.

The viral kinetic responses bear little relationship to the development of TD. It is not possible to assess the relationship between the early viral response (EVR), its associated viral load and the timing of TD development. This is because TD tends to develop approximately at the 18th week of treatment [10]. Furthermore, the critical end-point of this report is the assessment of SVR, irrespective of other landmark viral load studies during treatment. However, end of treatment responses (ETR) appear to confirm previous observation that it is often a reliable predictor of SVR. Most patients who achieved ETR also completed SVR except for the two genotype 1 patients who relapsed as defined by failure to achieve SVR. There was a 6-fold increase in the chance of achieving SVR with TD development for the pooled

| GENOTYPE 1 (N = 55) | Treatment regimens | Pegylated IFN-α2a and RBV 1000 mg | Pegylated IFN-α2a and RBV 1200 mg | Pegylated IFN-α2b and RBV 1000 mg | Pegylated IFN-α2b and RBV 1200 mg |
|---------------------|---------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| EVR*                | Control             | TD                                | Control                            | TD                                | Control                            | TD                                |
| ETR - number (%)    | 16                  | 4                                 | 12                                 | 3                                 | 8                                 | 8                                 |
| SVR - number (%)    | 8                   | 2                                 | 3                                 | 2                                 | 4                                 | 2                                 |

| GENOTYPE 3 (N = 40) | Treatment regimens | Pegylated IFN-α2a and RBV 800 mg | Pegylated IFN-α2b and RBV 800 mg |
|---------------------|---------------------|-----------------------------------|-----------------------------------|
| EVR*                | Control N = 16      | TD                                | Control N = 4                     | TD                                |
| ETR - number (%)    | 16                  | 4                                 | 16                                | 4                                 |
| SVR for genotype 1: Odds Ratio, 95% CI | Control (n = 32) 100.0% | TD (n = 8) 100.0% |
| SVR for genotype 3 | All 40 cases achieved SVR making the combination of Genotype 3 and TD a perfect predictor of SVR in this group. |

Treatment related SVR IFN-α2a vs IFNα2b Non Statistically Significant

OVERALL SVR: ODDS RATIO, 95% CI 6.0, 1.5 to 24.6
group containing all genotypes (odds ratio, 6.0; 95% confidence interval, 1.5 to 24.6). The likelihood of achieving SVR was increased in individuals with genotype 1 HCV infection who developed TD (odds ratio, 5.2; 95% confidence interval, 1.2 to 22.3). All genotype 3 patients who developed TD achieved SVR. Although our control cohort has a SVR rate of 100%, the overall reported and accepted rate approximates 80%, perhaps suggesting an additional synergistic effect in this genotype subgroup. Because of this overall high response rate and in order to quantify this amplified increment, there would need to be a much larger cohort. This is unlikely to be achievable given the low incidence of true TD occurring in this setting.

Whilst the thyroid gland is clearly implicated in this study, it remains undetermined whether thyroiditis is a mediator or the result of processes leading to SVR. While the development of a more effective immune response to HCV may unmask underlying thyroid autoimmune tendencies, it is also possible that acute exposure to supraphysiological concentrations of thyroid hormones (THs) may confer favourable immunomodulating activities leading to SVR. It is not yet known if the behaviour of the thyroid conditions in this setting is any different from those arising de novo and hence provides differing influences on the final hepatic viral status.

HCV infection results in the induction of IFN-α and -β production as part of the innate immune response [14], with subsequent activation of natural killer cells, maturation and proliferation of dendritic cells, proliferation of memory T cells, and prevention of T-cell apoptosis [15]. These effects are important in the mediation of a heightened tendency toward organ-specific autoimmune (including TD) in patients with HCV. The addition of exogenous IFN-α potentiates the risk of inflammatory autoimmunity in an already vulnerable and primed thyroid gland.

The exposure to the two different forms of IFN-α may be a potential confounder in eliciting SVR. These two IFNs differ significantly in their pegylation characteristics which may translate into their pharmacokinetics and biological activity. Recent reports indicated that there was a slightly higher SVR rate with pegylated IFN-α2a compared with α2b [16]. However, recent practice guidelines did not distinguish between the two in their recommendations [17-19]. There appears to be insufficient data to guide preference of one over the other. Similarly, our findings do not indicate any difference in SVR with regards to the two types of IFN-α, but again this is due to the small numbers.

The second potential influencing factor is the exposure to THs. Normal levels are unlikely to be effective as all other euthyroid and treated patients would otherwise have normal circulating levels. However, the presence of THs in vitro also potentiates the antiviral action of IFN in cultured human cells [13]. In the presence of IFN, THs can enhance the immunomodulation such as HLA-DR antigen expression (15). It is therefore possible but highly speculative that the favorable outcome seen in these patients is related to the exposure to supraphysiological concentrations of THs. However, it is equally possible that THs are not involved but is a mere para-phenomenon in a vigorous and exaggerated response to IFN therapy.

Finally, the recent discovery of the association between single nucleotide polymorphisms (SNPs) near the interleukin (IL) 28B gene locus showed that this plays an important part in the spontaneous recovery, response to treatment and attaining SVR from HCV infection [20-23]. This SNP may reflect differential levels of the immunomodulating cytokine IFN-λ-3, but the possibility that individuals at higher risk of TD development harbor favorable SNPs remains to be explored [24].

One of the shortcomings of this report is the small sample size, due primarily to the low prevalence of the condition. This was a major determinant of the choice of study design, with nested case-control studies offering important data on relatively uncommon end-points with little potential for additional bias. Nevertheless, collaboration with prominent centers would potentially allow prospective designs to be pursued, hence enhancing the power of the study; such studies would require standardization of thyroid surveying and definitions of thyroid disease. Secondly, there may be different genetic or regional differences as other reports, albeit retrospective, failed to find such a consistent pattern of SVR amongst TD cases [25-27]. The sampling of both cases and controls from the same patient cohort reduced the chance of selection bias.

Clinical implications

The finding from this study tentatively raises the question of whether thyroxine might be useful as an adjuvant addition to the treatment armamentarium. It is critical that this finding is confirmed (or refuted) by larger and independent studies because recent data suggested that in HCV cases with SVR, cirrhosis and its associated morbidities can be reversible [28].

Conclusions

This nested case-control study strongly indicates that TD is associated with a higher chance of achieving SVR, especially in genotype 1. This association mandates larger prospective multicentre trials to conclusively address this hypothesis if thyroxine is to be considered a potential adjuvant to current treatment regimen.
Acknowledgements
We would like to sincerely thank Geoffrey M Kellerman for his review and constructive comments of this manuscript.

Author details
1Hunters Area Pathology Service and University of Newcastle, Locked Bag Number 1, Hunter Mail Region Centre, Newcastle, New South Wales 2310, Australia. 2Hepatitis C Service, Gastroenterology Department, John Hunter Hospital and University of Newcastle, Locked Bag Number 1, Hunter Mail Region Centre, Newcastle, New South Wales 2310, Australia.

Authors’ contributions
HAT conceived the study, participated in its design, assisted with data collection and statistical analysis, and coordinated and helped to draft the manuscript. GEMR contributed to the statistical and meta-analytical methods, and participated in the discussion and drafting of the manuscript. TLJ, RG gathered, provided the data, and participated in the discussion and drafting of the manuscript. All authors read and approved the final revised manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 23 August 2010 Accepted: 24 May 2011
Published: 24 May 2011

References
1. World Health Organisation. Hepatitis C. Factsheet No. 164, 2000 [http://www.who.int/mediacentre/factsheets], accessed 20-May-2011.
2. Third National Hepatitis C Strategy 2010-2013. 2011 [http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-national-strategies-2010-hcv/SFile/hcv.pdf].
3. Armstrong GL, Wesley N, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
4. Dienstag JL. Hepatitis C: A bitter harvest. Ann Intern Med 2006, 144:770-771.
5. Shephard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
6. Tran HA. Hepatitis C infection, treatment regimens, and thyroid function abnormalities. The Endocrinologist 2007, 17:231-235.
7. Yan KK, Gurgui M, Ding T, George J, Dev A, Lee A, Zekry A. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol 2008, 14:3416-3420.
8. Patel K, Murr AJ, McHutchison JG. Diagnosis and treatment of chronic hepatitis C infection. BMJ 2006, 332:1013-7.
9. Tran HA, Reeves GEM, Gibson R, Atta JR. Development of thyroid diseases in the treatment of chronic hepatitis C with α-interferon may be a good prognosticator in achieving a sustained virologic response: A meta-analysis. J Gastroenterol Hepatol 2009, 24:1163-1168.
10. Tran HA, Reeves GEM, Jones TL. The natural history of interferon-alpha2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection. QJM 2009, 102:117-22.
11. Manns MP, Wedemeyer H, Comberg T. Treating viral hepatitis C: efficacy, side effects and complications. Gut 2006, 55:150-1599.
12. Rotondi M, Minelli R, Magi F, Leporati P, Romagnani P, Baroni MC, Delignone R, Sero M, Chiovato L. Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-alpha therapy for hepatitis C virus-related hepatitis. Eur J Endocrinol 2007, 156:409-14.
13. Lin HY, Thacore HR, Davis PJ, David FB. Thyroid hormone potentiates the antiviral action of interferon-gamma in cultured human cells. J Clin Endocrinol Metab 1994, 79:62-5.
14. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009, 119:1745-1754.
15. Hiroshi K, Eguchi J, Ishi S, Hisade A, Sakaki M, Doi H, Omori R, Imawari M. Immune response of cytotoxic T lymphocytes and possibility of vaccine development for hepatitis C virus infection. J Biomed Biotechnol 2010, 2010:263810.
16. Aghemo A, Grazi M, Colombo M. Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2010, 7:485-494.
17. Zeuzem S. Do differences in pegylation of interferon αα matter? Gastroenterology 2010, 138:34-36.
18. Avad T, Thorlund K, Hauser G, Stirnack D, Mbrouk M, Glaud C. Cochrane Hepato-Biliary Group. Peginterferon alpha-2a may achieve higher sustained response than peginterferon alpha-2b in chronic hepatitis C: a Cochrane systematic review of randomized clinical trial. Hepatology 2010, 51:1176-1184.
19. Ghany MG, Strader DB, Thomas DL, Scheckel JF. Diagnosis, Management, and Treatment of Hepatitis C. An Update. Hepatology 2009, 49:1335-1374.
20. Tanaka Y, Nishida N, Sugiyama M, Kurokai S, Matsuoka K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Higa S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiaa Y, Nishiguchi S, Koke A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, lizumi N, Tokunaga K, Mizakami M. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41:1105-1109.
21. Ge D, Fellyay J, Thompson A, Simons J, Shaikha K, Urban T, Heizen E, Qi P, Bertelsen A, Mui A, Suklowski M, McHutchinson J, Goldstein D. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
22. Tran HA, Tanaka Y, Nishida N, Sugiyama M, Kurokai S, Matsuoka K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Higa S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiaa Y, Nishiguchi S, Koke A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, lizumi N, Tokunaga K, Mizakami M. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy. Nat Genet 2009, 41:1100-1104.
23. Thomas D, Thio C, Martin M, Dongliang Ge Y, O’Hunio C, Kidd J, Kidd K, Khakoo S, Alexander G, Goodert J, Kirk G, Donfield S, Rosen H, Tobler L, Busch M, McHutchinson J, Goldstein D, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
24. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Wieland M, Abate M, Bassendine M, Spengler U, Don V, Powell E, Rondan S, Sehrdian D, Smedley A, Fragomeil V, Muller T, Bahlo M, Steward G, Booth D, George J, for the Hepatitis C Study. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009, 41:1100-1104.
25. Ahlenstiel G, Booth DR, George J. IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol 2010, 45:903-910.
26. Vezaiz E, Elefsinisiotis I, Mias C, Konstantinos E, Saroglio G. Thyroid dysfunction in patients with chronic hepatitis C: Virus- therapy-related? J Gastroenterol Hepatol 2009, 24:1024-1029.
27. Vezali E, Elefsinisiotis I, Mias C, Konstantinos E, Saroglio G. Thyroid dysfunction in patients with chronic hepatitis C: Virus- therapy-related? J Gastroenterol Hepatol 2009, 24:1024-1029.
28. Kee KM, Lee CM, Wang JH, Tung HD, Changchien CS, Lu SN, Wang P-W. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: Incidence, associated factors and prognosis. J Gastroenterol Hepatol 2006, 21:319-326.
29. Moncayo C, Leymarie F, Delmer B, Levy S, Bernard-Chabert B, Bouche O, Jolly D, Diebold MD, Cadiot G, Thiefin G. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: Incidence, associated factors and prognosis. J Gastroenterol Hepatol 2006, 21:319-326.
30. Moncayo C, Leymarie F, Delmer B, Levy S, Bernard-Chabert B, Bouche O, Jolly D, Diebold MD, Cadiot G, Thiefin G. Risk factors and long-term course of thyroid dysfunction during anti-viral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol 2003, 27:319-345.
31. Mallet V, Gilgenkrantz H, Serpaggi J, Verkade V, Vallet-Pichard A, Fontaine H, Pol S. Effective treatment of hepatitis C often results in regression of cirrhosis and a reduced risk for cirrhosis-related complications. Ann Intern Med 2008, 149:399-403.

Cite this article as: Tran et al. Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy: A nested case control study. BMC Endocrine Disorders 2011 11:10.